Pipeline | UCB

Pipeline

Our researchers, assisted by world class facilities and ground-breaking scientific platforms, are continually evolving and improving our science, their knowledge and capabilities. This has fueled a strong pipeline spanning several therapy areas that we are confident will deliver highly differentiated solutions.

bimekizumab (IL-17 A/F)

Type: Monoclonal antibody
Bimekizumab is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

• Therapeutic Area: Immunology
• Indications:
  • Hidradenitis Suppurativa (>9y / 12y-18y) — Topline results in H1 2027
  • Palmoplantar Pustulosis (PPP) — Topline results in 2028
  • Psoriasis (6y-18y) — Topline results in H2 2027
  • Juvenile Idiopathic Arthritis (2y-18y) — Topline results in 2028

rozanolixizumab (FcRn inhibitor)

Type: Monoclonal antibody
Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies.

• Therapeutic Area: Neurology
• Indications:
  • Myelin oligodendrocyte glycoprotein (MOG) antibody disease — Topline results in H2 2027 (event driven)
  • Ocular myasthenia gravis — Phase 3 initiated - Topline results in 2029

fenfluramine (5-HT and sigma-1 receptors)

Type: Small molecule
Fenfluramine is an investigational serotonin releasing agent, that has shown to stimulate multiple 5-HT receptor sub-types through the release of serotonin.

• Therapeutic Area: Neurology
• Indications:
  • CDKL5 deficiency disorder — Filed
  • RETT-Syndrome — Phase 3 initiated - Topline results in 2029

dapirolizumab pegol (anti-CD40L antibody)

Type: Monoclonal antibody
Dapirolizumab pegol is an investigational humanised monovalent pegylated Fab antibody fragment against the CD40 ligand (CD40L).

• Therapeutic Area: Immunology
• Indications:
  • Systemic lupus erythematosus — Topline results of 2nd phase 3 in 2028

STACCATO® alprazolam (benzodiazepine)

Type: Small molecule
STACCATO® alprazolam is an investigational drug-device combination using STACCATO® delivery technology with alprazolam, a benzodiazepine.

• Therapeutic Area: Neurology
• Indications:
  • Stereotypical prolonged seizures — Topline results in Q4 2026 / H1 2027 (event driven)

rezanecel (GABA interneuron cell therapy)

Type: Cell therapy
Rezanecel is an investigational allogenic regenerative GABA interneuron cell therapy, administered in a one-time, minimally invasive delivery procedure.

• Therapeutic Area: Neurology
• Indications:
  • Mesial Temporal Lobe Epilepsy — Phase 3 to start in H1 2027

bepranemab (anti-tau antibody)

Type: Monoclonal antibody
Bepranemab is an investigational recombinant, humanised, full length IgG4 monoclonal anti-tau antibody.

• Therapeutic Area: Neurology
• Indications:
  • Alzheimer's disease — Signal-confirming Phase 2 to start in H1 2027

glovadalen (D1 receptor positive allosteric modulators)

Type: Small molecule
Glovadalen is an investigational selective dopamine D1 receptor positive allosteric modulator.

• Therapeutic Area: Neurology
• Indications:
  • Parkinson's disease — Positive Phase 2a. Next steps under evaluation

galvokimig (IL-13 & IL-17 A/F)

Type: Multi-specific antibody
Galvokimig is a multispecific antibody–based therapeutic that inhibits IL-13, IL-17A and IL-17F.

• Therapeutic Area: Immunology
• Indications:
  • Atopic dermatitis — Phase 2b - Topline results (52-week) in 2028
  • Non Cystic Fibrosis Bronchiectasis (NCFB) — Phase 2 initiated in Q3 2026 - Topline results in 2029
  • Chronic Obstructive Pulmonary Disease (COPD) — Phase 2 initiated in Q3 2026 - Topline results in 2029

cizutamig (BCMA x CD3 T-cell engager)

Type: Multi-specific antibody
Cizutamig is an investigational bispecific antibody directed to B-cell maturation antigen (BCMA).

• Therapeutic Area: Immunology
• Indications:
  • Myasthenia gravis & Systemic autoimmune rheumatic disease associated interstitial lung disease — Phase 2 planned to start end 2026